Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022
Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, Bossi P, Chilles A, Corby PM, Epstein JB, Elad S, Fekrazad R, Fregnani ER, Genot MT, Ibarra AMC, Hamblin MR, Heiskanen V, Hu K, Klastersky J, Lalla R, Latifian S, Maiya A, Mebis J, Migliorati CA, Milstein DMJ, Murphy B, Raber-Durlacher JE, Roseboom HJ, Sonis S, Treister N, Zadik Y, Bensadoun RJ
Frontiers in oncology · 120 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-08-30 · Front Oncol · vol. 12 · pág. 927685
- Editorial
- Frontiers Media
- Citado
- 174 citas · más que el 100% de estudios similares · 19.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 270 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Oral health in cancer treatment · Laser Applications in Dentistry and Medicine · Oral Health Pathology and Treatment
- Palabras clave
- Medicine, Mucositis, Radiation therapy, Intensive care medicine, Cancer, Clinical trial, Position paper, Head and neck cancer, Quality of life (healthcare), Medical physics, Nice, Surgery, Internal medicine, Pathology
33 autores
- Jolien Robijns🇧🇪Hasselt University
- RAJ G. NAIR🇦🇺Griffith University; Gold Coast Hospital
- Joy Lodewijckx🇧🇪Hasselt University
- Praveen Ravindra Arany🇺🇸University at Buffalo, State University of New York
- Andrei Barasch🇺🇸Harvard University
- Jan Magnus Bjordal🇳🇴University of Bergen
- Paolo Bossi🇮🇹University of Brescia
- Anne Chilles🇫🇷Institut Curie
- Patricia M A Corby🇺🇸Center for Clinical Research (United States); New York University; New York College of Health Professions
- Joel Brian Epstein🇺🇸City Of Hope National Medical Center; City of Hope; Sinai Health System
- Sharon Elad🇺🇸University of Rochester Medicine; Eastman Chemical Company (United States)
- Reza Fekrazad🇮🇷Aja University of Medical Sciences
- Eduardo Rodrigues Fregnani🇧🇷Hospital Sírio-Libanês
- Marie-Thérèse Genot🇧🇪Université Libre de Bruxelles; Institut Jules Bordet
- Ana Melissa Ccopa Ibarra🇧🇷Universidade Nove de Julho
- Michael R. Hamblin🇺🇸Harvard University; Massachusetts General Hospital
- Vladimir Heiskanen🇫🇮University of Helsinki
- K.S. Hu🇺🇸NYU Langone Health
- Jean A. Klastersky🇧🇪Institut Jules Bordet
- Rajesh Lalla🇺🇸University of Connecticut
- Sofia Latifian🇧🇪Institut Jules Bordet
- Arun Gundmi Maiya🇮🇳Manipal Academy of Higher Education
- Jeroen Mebis🇧🇪Hasselt University
- Cesar Augusto Migliorati🇺🇸University of Florida; Florida College
- Dan M.J. Milstein🇳🇱Amsterdam UMC Location University of Amsterdam; University of Amsterdam
- Barbara A. Murphy🇺🇸Vanderbilt University Medical Center
- Judith E. Raber‐Durlacher🇳🇱Academic Center for Dentistry Amsterdam; Amsterdam University Medical Centers; University of Amsterdam
- Hendrik J. Roseboom🇳🇱Academic Center for Dentistry Amsterdam; Amsterdam University Medical Centers; University of Amsterdam
- Stephen T. Sonis🇺🇸🇨🇦Brigham and Women's Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center; Institute of Infection and Immunity
- Nathaniel Simon Treister🇺🇸🇨🇦Brigham and Women's Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center; Institute of Infection and Immunity
- Yehuda Zadik🇮🇱Hebrew University of Jerusalem
- René‐Jean Bensadoun🇫🇷 · autor de correspondenciaCentre de Haute Energie
- “Cancer Supportive Care” WALT Working Group
Resumen
El texto original del estudio, en el idioma en que se publicó.
Disclaimer
This article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols.
Objective
This position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).
Background
There is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients' quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care.
Methods
A literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed.
Results
There is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors.
Conclusions
There is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.